# US 2021/0332099 A1 · Pharmaceutical preparation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332099 A1
- Document ID: US20210332099A1
- Status: Published application
- Kind: A1
- Application number: 17/246,348
- Filed: 2021-04-30
- Published: 2021-10-28
- Earliest claimed: 2008-04-16
- Assignees: Ferring International Center S.A.
- Applicants: Ferring International Center SA
- Inventors: Ian COTTINGHAM; Daniel PLAKSIN; Richard Boyd WHITE
- Web page: https://patentgrep.com/patent/US20210332099A1

## CPC

- C07K 14/59: Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- A61P 5/06: of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P 5/10: of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- C12N 9/1081: {transferring other glycosyl groups (2.4.99)}
- C12Y 204/99: transferring other glycosyl groups (2.4.99)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Preparations including recombinant FSH (rFSH).

## Claims

### Claim 1

Recombinant follicle stimulating hormone (FSH) comprising α2,3- and α2,6-sialylation, produced or expressed in a human cell line, wherein from 5% to 20% of the total sialylation of the recombinant FSH is α2,6-sialylation.

### Claim 2

A method of manufacturing recombinant follicle stimulating hormone (FSH) comprising α2,3- and α2,6-sialylation, the method comprising producing or expressing recombinant FSH in a human cell line, wherein the human cell line has been modified using an α2,3-sialyltransferase.

### Claim 3 (depends on 2)

The method of claim 2, wherein the human cell line has endogenous α2,6-sialyltransferase activity.

### Claim 4 (depends on 2)

The method of claim 2, wherein the human cell line is a PER.C6® cell line.

### Claim 5 (depends on 2)

The method of claim 2, wherein the human cell line is a PER.C6® cell line that has endogenous α2,6-sialyltransferase activity.

### Claim 6 (depends on 2)

The method of claim 2, wherein the recombinant FSH comprises α2,3- and α2,6-sialylation, and wherein from 5% to 20% of the total sialylation of the recombinant FSH is α2,6-sialylation.

### Claim 7 (depends on 2)

Recombinant FSH (rFSH) produced by the method of claim 2.

### Claim 8 (depends on 4)

Recombinant FSH (rFSH) produced by the method of claim 4.

### Claim 9 (depends on 6)

Recombinant FSH (rFSH) produced by the method of claim 6.
